Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine--a comparison of 1- and 3-month immunization schedules.
Live attenuated SA14-14-2 Japanese encephalitis (JE) vaccine has been safe and effective in >100 million immunized children, but its current administration schedule of two doses given a year apart does not lend itself to inclusion in established Expanded Program of Immunization (EPI) schedules of childhood immunization. Immune responses to immunization at shorter intervals were compared in middle-school-aged children immunized with two doses separated by 1 month (n = 116) or 2.5 months (n = 115). Two vaccine lots were compared. Seroconversion to the vaccine was observed in 100% of vaccinees immunized in the 1-month schedule and in 94% (lot 2) and 100% (lot 1) of vaccinees immunized in the 2.5-month schedule. Geometric mean titers were almost 2-fold higher with the longer schedule. The routine administration of JE SA14-14-2 vaccine to infants in an EPI schedule should be possible using either interval.
Tsai
T F
TF
Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Ft. Collins, Colorado, USA.
Yu
Y X
YX
Jia
L L
LL
Putvatana
R
R
Zhang
R
R
Wang
S
S
Halstead
S B
SB
D000293:Adolescent; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis* / Q000276:immunology; D002478:Cells, Cultured; D002648:Child; D002522:Chlorocebus aethiops; D004672:Encephalitis, Japanese / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007115:Immunization Schedule; D009500:Neutralization Tests; D014613:Vaccines, Attenuated / Q000008:administration & dosage* / Q000276:immunology; D014709:Vero Cells; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines